A citation-based method for searching scientific literature

Bryce C Simes, Gordon G MacGregor.  2019
Times Cited: 5







List of co-cited articles
8 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N. Engl. J. Med. 2017
60

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.
Michael Roden, Jianping Weng, Jens Eilbracht, Bruno Delafont, Gabriel Kim, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2013
257
40

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N. Engl. J. Med. 2015
40

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N. Engl. J. Med. 2019
951
40


SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials.
Robert Puckrin, Marie-Philippe Saltiel, Pauline Reynier, Laurent Azoulay, Oriana H Y Yu, Kristian B Filion. Acta Diabetol 2018
43
40


SGLT2 inhibitors with cardiovascular benefits: Transforming clinical care in Type 2 diabetes mellitus.
Michael d'Emden, John Amerena, Gary Deed, Carol Pollock, Mark E Cooper. Diabetes Res. Clin. Pract. 2018
10
40

Characterization of [¹²⁵I]GLP-1(9-36), a novel radiolabeled analog of the major metabolite of glucagon-like peptide 1 to a receptor distinct from GLP1-R and function of the peptide in murine aorta.
Rhoda E Kuc, Janet J Maguire, Keith Siew, Sheena Patel, David R Derksen, V Margaret Jackson, Kevin M O'Shaughnessey, Anthony P Davenport. Life Sci. 2014
5
20



Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
Anthony H Barnett, Ambrish Mithal, Jenny Manassie, Russell Jones, Henning Rattunde, Hans J Woerle, Uli C Broedl. Lancet Diabetes Endocrinol 2014
287
20

Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type 2 diabetes.
F Xavier Pi-Sunyer, Anja Schweizer, David Mills, Sylvie Dejager. Diabetes Res. Clin. Pract. 2007
208
20

Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus.
Michael J Barry, Linda L Humphrey, Amir Qaseem. Ann. Intern. Med. 2017
2
50

Standards of medical care for type 2 diabetes in China 2019.
Weiping Jia, Jianping Weng, Dalong Zhu, Linong Ji, Juming Lu, Zhiguang Zhou, Dajin Zou, Lixin Guo, Qiuhe Ji, Li Chen,[...]. Diabetes Metab. Res. Rev. 2019
46
20

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors.
A J Scheen. Diabetes Obes Metab 2010
170
20

The oral DPP-4 inhibitor linagliptin significantly lowers HbA1c after 4 weeks of treatment in patients with type 2 diabetes mellitus.
T Forst, B Uhlig-Laske, A Ring, A Ritzhaupt, U Graefe-Mody, K A Dugi. Diabetes Obes Metab 2011
43
20


Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes.
Markolf Hanefeld, Gary A Herman, Mei Wu, Carolyn Mickel, Matilde Sanchez, Peter P Stein. Curr Med Res Opin 2007
115
20

Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes.
Mikaela Sjöstrand, Nayyar Iqbal, Jane Lu, Boaz Hirshberg. Diabetes Res. Clin. Pract. 2014
9
20

[Disturbances of lipoprotein metabolism in metabolic syndrome].
Marta Czyzewska, Anna Wolska, Agnieszka Cwiklińska, Barbara Kortas-Stempak, Małgorzata Wróblewska. Postepy Hig Med Dosw (Online) 2010
4
25

GRADE guidelines: 3. Rating the quality of evidence.
Howard Balshem, Mark Helfand, Holger J Schünemann, Andrew D Oxman, Regina Kunz, Jan Brozek, Gunn E Vist, Yngve Falck-Ytter, Joerg Meerpohl, Susan Norris,[...]. J Clin Epidemiol 2011
20

Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes.
B Bode, K Stenlöf, S Harris, D Sullivan, A Fung, K Usiskin, G Meininger. Diabetes Obes Metab 2015
120
20

SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study.
Muhammad Abdul-Ghani, Stefano Del Prato, Robert Chilton, Ralph A DeFronzo. Diabetes Care 2016
144
20

The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients.
Aino Latva-Rasku, Miikka-Juhani Honka, Joel Kullberg, Nina Mononen, Terho Lehtimäki, Juha Saltevo, Anna K Kirjavainen, Virva Saunavaara, Patricia Iozzo, Lars Johansson,[...]. Diabetes Care 2019
18
20

Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation.
Larissa Shamseer, David Moher, Mike Clarke, Davina Ghersi, Alessandro Liberati, Mark Petticrew, Paul Shekelle, Lesley A Stewart. BMJ 2015
20


Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
Hans-Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Marc Weimer, Thomas Meinicke, Uli C Broedl, Hans J Woerle. Diabetes Care 2014
222
20

Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses.
Xin Sun, Matthias Briel, Stephen D Walter, Gordon H Guyatt. BMJ 2010
343
20

Pathophysiology of Diabetic Dyslipidemia.
Tsutomu Hirano. J. Atheroscler. Thromb. 2018
32
20

The effects of clinical and statistical heterogeneity on the predictive values of results from meta-analyses.
W G Melsen, M C J Bootsma, M M Rovers, M J M Bonten. Clin. Microbiol. Infect. 2014
129
20

Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
Heidi Storgaard, Lise L Gluud, Cathy Bennett, Magnus F Grøndahl, Mikkel B Christensen, Filip K Knop, Tina Vilsbøll. PLoS ONE 2016
71
20

Dapagliflozin decreases small dense low-density lipoprotein-cholesterol and increases high-density lipoprotein 2-cholesterol in patients with type 2 diabetes: comparison with sitagliptin.
Toshiyuki Hayashi, Tomoyasu Fukui, Noriko Nakanishi, Saki Yamamoto, Masako Tomoyasu, Anna Osamura, Makoto Ohara, Takeshi Yamamoto, Yasuki Ito, Tsutomu Hirano. Cardiovasc Diabetol 2017
49
20

Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study (JDCS).
Hirohito Sone, Sachiko Tanaka, Shiro Tanaka, Satoshi Iimuro, Koji Oida, Yoshimitsu Yamasaki, Shinichi Oikawa, Shun Ishibashi, Shigehiro Katayama, Yasuo Ohashi,[...]. J. Clin. Endocrinol. Metab. 2011
109
20


Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.
Ele Ferrannini, Elza Muscelli, Silvia Frascerra, Simona Baldi, Andrea Mari, Tim Heise, Uli C Broedl, Hans-Juergen Woerle. J. Clin. Invest. 2014
506
20

Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL.
Lindsay E Clegg, Hiddo J L Heerspink, Robert C Penland, Weifeng Tang, David W Boulton, Srinivas Bachina, Robert D Fox, Peter Fenici, Marcus Thuresson, Robert J Mentz,[...]. Diabetes Care 2019
8
20

Recent progress of sodium-glucose transporter 2 inhibitors as potential antidiabetic agents.
Yajing Zhang, Huazhuo Ban, Runan Yu, Zhijian Wang, Dayong Zhang. Future Med Chem 2018
1
100


New insights into the pathophysiology of dyslipidemia in type 2 diabetes.
Marja-Riitta Taskinen, Jan Borén. Atherosclerosis 2015
146
20

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk.
Anastasia Erythropoulou-Kaltsidou, Georgios Polychronopoulos, Konstantinos Tziomalos.  2020
3
33


Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes.
Chantal Mathieu, Aurelian Emil Ranetti, Danshi Li, Ella Ekholm, William Cook, Boaz Hirshberg, Hungta Chen, Lars Hansen, Nayyar Iqbal. Diabetes Care 2015
69
20

The efficacy and safety of once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus: A systemic review and meta-analysis.
Xianying Wang, Xuejing Li, Suhui Qie, Yingying Zheng, Yang Liu, Guoqiang Liu. Medicine (Baltimore) 2018
4
25

Sequential Treatment Escalation with Dapagliflozin and Saxagliptin Improves Beta Cell Function in Type 2 Diabetic Patients on Previous Metformin Treatment: An Exploratory Mechanistic Study.
Thomas Forst, Mohammed Khaled Alghdban, Annelie Fischer, Matthias M Weber, Stephan Voswinkel, Tim Heise, Christoph Kapitza, Leona Plum-Mörschel. Horm. Metab. Res. 2018
5
20



A network meta-analysis for efficacy and safety of seven regimens in the treatment of type II diabetes.
Li-Guo Wang, Hui Wang, Qin Liu, Wei-Chang Hua, Chang-Ming Li. Biomed. Pharmacother. 2017
3
33

Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
Nancy A Thornberry, Baptist Gallwitz. Best Pract. Res. Clin. Endocrinol. Metab. 2009
79
20



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.